Key TakeawaysModerna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two-month pennant pattern, setting the stage for a potential continuation move lower.Investors should watch crucial support levels on Moderna's chart around $30 and $13, while also monitoring key resistance levels near $57 and $68. Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plungin ...